Sort
10,766 grants matching “checkpoint inhibitor”
DKK2 regulates NK activation and tumor immunity
$503,046Dianqing Wu · Yale University · R01 · FY2022 · CA
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma
$502,859J. Silvio Gutkind · University Of California, San Diego · R01 · FY2024 · CA
The Adenosinergic Pathway in Tumor-derived Exosomes
$502,792Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
$502,655Periasamy Selvaraj · Emory University · R01 · FY2016 · CA
Exploring the potential of TET inhibition in cancer immunotherapy
$502,630Anjana Rao · La Jolla Institute For Immunology · R01 · FY2020 · CA
Exploring the potential of TET inhibition in cancer immunotherapy
$502,630Anjana Rao · La Jolla Institute For Immunology · R01 · FY2021 · CA
CHI3L1-targeted small molecules for glioblastoma
$502,588Moustafa Gabr · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · NS
CHI3L1-targeted small molecules for glioblastoma
$502,588Moustafa Gabr · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · NS
Novel synthetic lethality strategy for TP53 mutant colorectal cancer
$502,520Christos Fountzilas · Roswell Park Cancer Institute Corp · R37 · FY2024 · CA
Systems analysis of mechanisms driving response to immunotherapy in clear cell cancers
$502,504Andrew J. Gentles · Stanford University · U01 · FY2023 · CA
The c-Rel Checkpoint for Immunosuppression and Immunotherapy
$502,487Warren S Pear · University Of Pennsylvania · R01 · FY2022 · AI
The c-Rel Checkpoint for Immunosuppression and Immunotherapy
$502,487Warren S Pear · University Of Pennsylvania · R01 · FY2024 · AI
The c-Rel Checkpoint for Immunosuppression and Immunotherapy
$502,487Warren S Pear · University Of Pennsylvania · R01 · FY2023 · AI
Molecular Targeting of Diffuse Large B-cell Lymphoma
$502,192Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R01 · FY2014 · CA
Mechanistic analyses of a novel RNA polymerase I transcription checkpoint
$502,070Marikki Laiho · Johns Hopkins University · R01 · FY2017 · GM
IDO1 and Immunotolerance in Glioblastoma
$502,054Derek Alan Wainwright · Loyola University Chicago · R01 · FY2025 · NS
IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
$502,010Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2024 · CA
Role of Meis1 in Regulation of Cardiomyocyte Proliferation
$501,998Hesham Sadek · Ut Southwestern Medical Center · R01 · FY2014 · HL
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
$501,962Eric T Ahrens · University Of California, San Diego · R01 · FY2019 · CA
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
$501,827Xiongbin Lu · Indiana University Indianapolis · R01 · FY2022 · CA
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
$501,827Xinna Zhang · Indiana University Indianapolis · R01 · FY2025 · CA
Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.
$501,790Gordon B. Mills · Oregon Health & Science University · U01 · FY2024 · CA
Evaluation of Immune-based Combinations in Prostate Cancer
$501,693Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Investigating the roles of extracellular cGAMP and harnessing it for cancer treatment
$501,670Lingyin Li · Stanford University · R01 · FY2021 · CA
HCMV regulation of monocyte/macrophage host cell signaling in viral reactivation
$501,605Andrew D Yurochko · Oregon Health & Science University · P01 · FY2025 · AI